PCRX — Pacira Biosciences Share News
0.000.00%
Last trade - 00:00- $878.64m
- $1.04bn
- $726.41m
Brief: Pacira Biosciences' Pcrx-201 Granted Regenerative Medicine Advance Therapy (Rmat) Designation For The Treatment Of Osteoarthritis Of The Knee
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria'S Secret & Co
Pacira Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Pacira Biosciences FY Adjusted Net Income USD 142 Million
Pacira Biosciences Inc expected to post earnings of 88 cents a share - Earnings Preview
Pacira Biosciences Inc expected to post earnings of 88 cents a share - Earnings Preview
Brief: Pacira Appoints Frank D. Lee As Chief Executive Officer
Brief: Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
Pacira Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Pacira Biosciences Q3 Revenue USD 163.9 Million Vs. IBES Estimate USD 171.6 Million
Pacira Biosciences Inc expected to post earnings of 78 cents a share - Earnings Preview
Brief: Pacira Biosciences: David Stack To Retire As Chairman And CEO Once Successor Appointed
Pacira Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Pacira Biosciences Q2 Revenue USD 169.5 Million Vs. IBES Estimate USD 174.6 Million
Pacira Biosciences Inc expected to post earnings of 76 cents a share - Earnings Preview
Pacira BioSciences falls on Q1 profit miss
Pacira Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pacira Biosciences posts Q1 revenue USD 160.3 million
Brief: Pacira Biosciences Reports First Quarter 2023 Financial Results